Galectin-3 and cardiac resynchronization therapy
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Mar 18, 2014
Grant Date -
Mar 24, 2011
app pub date -
Aug 25, 2010
filing date -
Aug 25, 2009
priority date (Note) -
In Force
status (Latency Note)
Importance
Abstract
The present invention relates to materials and methods for monitoring and predicting a heart failure patient's physiological response to cardiac resynchronization therapy. More specifically, the present invention relates to the endogenous protein galectin-3 and its use in monitoring progression of disease in a patient undergoing cardiac resynchronization therapy, and as a predictor of response to cardiac resynchronization therapy.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully